MAI Capital Management grew its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 72,979 shares of the medical research company’s stock after acquiring an additional 1,514 shares during the quarter. Amgen comprises about 0.7% of MAI Capital Management’s holdings, making the stock its 29th largest position. MAI Capital Management’s holdings in Amgen were worth $13,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Pillar Pacific Capital Management LLC boosted its stake in shares of Amgen by 0.5% during the 2nd quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock valued at $10,461,000 after buying an additional 254 shares during the last quarter. Fairfield Bush & CO. boosted its stake in shares of Amgen by 0.8% during the 2nd quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock valued at $6,264,000 after buying an additional 260 shares during the last quarter. Advisors Capital Management LLC boosted its stake in shares of Amgen by 5.8% during the 2nd quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock valued at $874,000 after buying an additional 261 shares during the last quarter. Highland Capital Management LLC boosted its stake in shares of Amgen by 1.0% during the 2nd quarter. Highland Capital Management LLC now owns 27,457 shares of the medical research company’s stock valued at $5,068,000 after buying an additional 262 shares during the last quarter. Finally, Mutual Advisors LLC boosted its stake in shares of Amgen by 5.8% during the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after buying an additional 265 shares during the last quarter. 82.48% of the stock is owned by institutional investors.

In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.27% of the company’s stock.

Several equities analysts have recently commented on the company. Royal Bank of Canada reiterated a “neutral” rating and set a $193.00 target price on shares of Amgen in a research note on Monday, September 10th. Piper Jaffray Companies upped their price target on Amgen from $190.00 to $210.00 and gave the company an “overweight” rating in a research report on Thursday, July 26th. They noted that the move was a valuation call. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 11th. Cann reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Monday, July 30th. Finally, Oppenheimer reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $204.90.

Shares of NASDAQ:AMGN traded up $3.54 on Friday, hitting $197.39. The company’s stock had a trading volume of 2,784,524 shares, compared to its average volume of 3,571,043. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The stock has a market cap of $134.17 billion, a price-to-earnings ratio of 15.69, a PEG ratio of 2.02 and a beta of 1.40. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same quarter in the prior year, the business posted $3.27 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts predict that Amgen, Inc. will post 13.96 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Recommended Story: How a Put Option Works

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.